EDIT vs EQIX · rev $32.3M vs P/E 79, rev $9.22B
Editas Medicine Inc (EDIT) versus Equinix Inc (EQIX) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Equinix Inc (EQIX) is a reit - specialty company listed on US.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported EQIX revenue for 2025-12-31 was $9.22B. Net income was $1.35B. Revenue was up 5.4% from 2024-12-31 to 2025-12-31. EQIX currently screens at market cap $74.23B and trailing P/E 79.4.
EDIT currently screens at market cap $375.2M. EQIX currently screens at market cap $74.23B and trailing P/E 79.4.
Not investment advice. Open the EDIT and EQIX stock pages for the full models.
Not investment advice.